0001453687-22-000053.txt : 20220322 0001453687-22-000053.hdr.sgml : 20220322 20220322080028 ACCESSION NUMBER: 0001453687-22-000053 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220321 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220322 DATE AS OF CHANGE: 20220322 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SELECTA BIOSCIENCES INC CENTRAL INDEX KEY: 0001453687 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37798 FILM NUMBER: 22757209 BUSINESS ADDRESS: STREET 1: 65 GROVE STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-923-1400 MAIL ADDRESS: STREET 1: 65 GROVE STREET CITY: WATERTOWN STATE: MA ZIP: 02472 8-K 1 selb-20220321.htm 8-K selb-20220321
0001453687false00014536872022-03-212022-03-21

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 21, 2022
 
SELECTA BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
 
Delaware 001-37798 26-1622110
(State or other jurisdiction
of incorporation)
 (Commission
File Number)
 (IRS Employer
Identification No.)
 
65 Grove Street, Watertown, MA 02472
(Address of principal executive offices)(Zip Code)
 
(617) 923-1400
Registrant’s telephone number, including area code
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock (Par Value $0.0001)SELBThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 1.01 Entry into a Material Definitive Agreement.
On March 21, 2022, Selecta Biosciences, Inc. (the “Company”) entered into a Second Amendment to Loan and Security Agreement (the “Second Amendment”),which amended that certain Loan and Security Agreement, dated August 31, 2020, between the Company, Oxford Finance LLC, as collateral agent and as a lender, and Silicon Valley Bank, as a lender (as amended by that certain First Amendment to Loan and Security Agreement, dated September 7, 2021, and as further amended by the Second Amendment, the “Loan Agreement”).
The Second Amendment, among other things, extends the date on which amortization payments in respect of the term loan borrowed under the Loan Agreement (the “Term Loan”) will commence by twelve months to April 1, 2023. Thereafter, amortization payments will be paid monthly in equal installments of principal and interest to fully amortize the outstanding principal over the remaining term of the Term Loan, subject to recalculation upon a change in the prime rate.
The foregoing description of the Second Amendment is a summary, and is qualified in its entirety by reference to the Second Amendment which is filed herewith as Exhibit 10.1, and is incorporated herein by reference.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information regarding the Term Loan set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 2.03.

Item 8.01 Other Events.
The Company believes that its current cash, cash equivalents, and restricted cash as of the date of this filing will enable it to fund its current planned operations into the fourth quarter of 2023.

Item 9.01 Financial Statements and Exhibits.
(d) Exhibits



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 SELECTA BIOSCIENCES, INC.
  
  
Date: March 22, 2022By:/s/ Carsten Brunn, Ph.D.
  Carsten Brunn, Ph.D.
  President and Chief Executive Officer

EX-10.1 2 exhibit101_secondamendment.htm EX-10.1 Document
Exhibit 10.1
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT
THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of March 21, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 to the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender and SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman Drive, Santa Clara, CA 95054 (“Bank” or “SVB”) (each a “Lender” and collectively, the “Lenders”), and SELECTA BIOSCIENCES, INC., a Delaware corporation with offices located at 65 Grove Street, Suite 101, Watertown, MA 02472 (“Borrower”).
A.    WHEREAS, Collateral Agent, Borrower and Lenders have entered into that certain Loan and Security Agreement dated as of August 31, 2020 (as amended by that certain First Amendment to Loan and Security Agreement dated as of September 7, 2021 and as further amended, supplemented or otherwise modified from time to time, the “Loan Agreement”) pursuant to which Lenders have provided to Borrower certain loans in accordance with the terms and conditions thereof; and
B.    WHEREAS, Borrower has requested that Collateral Agent and Lenders (i) modify the Amortization Date and (ii) make certain other revisions to the Loan Agreement as more fully set forth herein; and
C.    WHEREAS, Borrower, the Lenders party to this Amendment (constituting the Required Lenders) and Collateral Agent desire to amend certain provisions of the Loan Agreement as provided herein and subject to the terms and conditions set forth herein.
Agreement
NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Borrower, Lenders and Collateral Agent hereby agree as follows:
1.    Definitions. Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.
2.    Amendments to Loan Agreement.
2.1    Section 2.2(b) (Repayment). Section 2.2(b) of the Loan Agreement is hereby amended by replacing Section 2.2(b) in its entirety with the following:
“(b)    Repayment. Borrower shall make monthly payments of interest only commencing on the first (1st) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date. Borrower agrees to pay, on the Funding Date of each Term Loan, any initial partial monthly interest payment otherwise due for the period between the Funding Date of such Term Loan and the first Payment Date thereof. Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive equal monthly payments of principal, together with applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon: (1) the amount of such Lender’s Term Loan, (2) the effective rate of interest, as determined in Section 2.3(a), and (3) a repayment schedule equal to twenty-nine (29) months commencing on the Amortization Date. All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date. Each Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).

2.2    Section 2.5(f) (Fees). Section 2.5 of the Loan Agreement is hereby amended by inserting the following new Section 2.5(f):
“(f)    Second Amendment Fee. A fully-earned, non-refundable amendment fee of One Hundred Ten Thousand Dollars ($110,000.00) to be shared between the Lenders pursuant to their Pro Rata Shares, which shall be due and payable on the Second Amendment Effective Date.


1



2.3    Section 13.1 (Definitions). The following terms and their respective definitions hereby are added or amended and restated in their entirety, as applicable, to Section 13.1 of the Loan Agreement as follows:
Amortization Date” is April 1, 2023.
Second Amendment Effective Date” means March 21, 2022.
3.    Limitation of Amendment.
3.1    The amendments set forth above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right, remedy or obligation which Lenders or Borrower may now have or may have in the future under or in connection with any Loan Document, as amended hereby.
3.2    This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents are hereby ratified and confirmed and shall remain in full force and effect.
4.    Representations and Warranties. To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:
4.1    Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date) and (b) no Event of Default has occurred and is continuing;
4.2    Borrower has the power and due authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;
4.3    The organizational documents of Borrower delivered to Collateral Agent on the Effective Date, and updated pursuant to subsequent deliveries by or on behalf of the Borrower to the Collateral Agent, remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;
4.4    The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not contravene (i) any material law or regulation binding on or affecting Borrower, (ii) any material contractual restriction with a Person binding on Borrower, (iii) any material order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (iv) the organizational documents of Borrower;
4.5    The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower, except as already has been obtained or made;
4.6    This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights.
5.    Release by Borrower.
5.1    FOR GOOD AND VALUABLE CONSIDERATION, Borrower hereby forever relieves, releases, and discharges Collateral Agent and each Lender and their respective present or former employees, officers, directors, agents, representatives, attorneys, and each of them, from any and all claims, debts, liabilities, demands, obligations, promises, acts, agreements, costs and expenses, actions and causes of action, of every type, kind, nature, description or character whatsoever, whether known or unknown, suspected or unsuspected, absolute or contingent, arising out of or in any manner whatsoever connected with or related to facts, circumstances, issues, controversies or claims existing or arising from the beginning of time through and including the date of execution of this Amendment solely to the extent such claims arise out of or are in any manner whatsoever connected with or related to the Loan Documents, the Recitals hereto, any instruments, agreements or documents executed in connection with any of the foregoing or the origination, negotiation, administration, servicing and/or enforcement of any of the foregoing (collectively “Released Claims”).

2


5.2    In furtherance of this release, Borrower expressly acknowledges and waives the provisions of California Civil Code Section 1542 (and any similar provision under the laws of any state), which states:
“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”

5.3    By entering into this release, Borrower recognizes that no facts or representations are ever absolutely certain and it may hereafter discover facts in addition to or different from those which it presently knows or believes to be true, but that it is the intention of Borrower hereby to fully, finally and forever settle and release all matters, disputes and differences, known or unknown, suspected or unsuspected in relation to the Released Claims; accordingly, if Borrower should subsequently discover that any fact that it relied upon in entering into this release was untrue, or that any understanding of the facts was incorrect, Borrower shall not be entitled to set aside this release by reason thereof, regardless of any claim of mistake of fact or law or any other circumstances whatsoever. Borrower acknowledges that it is not relying upon and has not relied upon any representation or statement made by Bank with respect to the facts underlying this release or with regard to any of such party’s rights or asserted rights.
5.4    This release may be pleaded as a full and complete defense and/or as a cross-complaint or counterclaim against any action, suit, or other proceeding that may be instituted, prosecuted or attempted in breach of this release. Borrower acknowledges that the release contained herein constitutes a material inducement to Collateral Agent and the Lenders to enter into this Amendment, and that Collateral Agent and the Lenders would not have done so but for Collateral Agent’s and the Lenders’ expectation that such release is valid and enforceable in all events.
6.    Effectiveness. This Amendment shall be deemed effective as of the date hereof upon (a) the due execution of this Amendment by the parties thereto, and (b) the receipt by the Lenders of an amendment fee in the amount of One Hundred Ten Thousand Dollars ($110,000.00) in accordance with Section 2.5(f) of the Loan Agreement, as amended by this Amendment.
7.    Counterparts. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same instrument. Delivery by electronic transmission (e.g. “.pdf”) of an executed counterpart of this Amendment shall be effective as a manually executed counterpart signature thereof.
8.    Governing Law. This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in accordance with the laws of the State of California.

[Balance of Page Intentionally Left Blank]


3



IN WITNESS WHEREOF, the parties hereto have caused this Second Amendment to Loan and Security Agreement to be executed as of the date first set forth above.
BORROWER:
SELECTA BIOSCIENCES, INC.
By:/s/ Kevin Tan
Name:Kevin Tan
Title:Chief Financial Officer
COLLATERAL AGENT AND LENDER:
OXFORD FINANCE LLC
By:/s/ Colette H. Featherly
Name:Colette H. Featherly
Title:Senior Vice President
LENDER:
SILICON VALLEY BANK
By:/s/ Lauren Cole
Name:Lauren Cole
Title:Director




[Signature Page to Second Amendment to Loan and Security Agreement]

4
EX-101.SCH 3 selb-20220321.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 selb-20220321_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 5 selb-20220321_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover Page Document
Mar. 21, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Mar. 21, 2022
Entity Registrant Name SELECTA BIOSCIENCES, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-37798
Entity Tax Identification Number 26-1622110
Entity Address, Address Line One 65 Grove Street,
Entity Address, City or Town Watertown,
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code 617
Local Phone Number 923-1400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock (Par Value $0.0001)
Trading Symbol SELB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001453687
Amendment Flag false
XML 7 selb-20220321_htm.xml IDEA: XBRL DOCUMENT 0001453687 2022-03-21 2022-03-21 0001453687 false 8-K 2022-03-21 SELECTA BIOSCIENCES, INC. DE 001-37798 26-1622110 65 Grove Street, Watertown, MA 02472 617 923-1400 false false false false Common Stock (Par Value $0.0001) SELB NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Document Sheet http://www.selectabio.com/role/CoverPageDocument Cover Page Document Cover 1 false false All Reports Book All Reports selb-20220321.htm exhibit101_secondamendment.htm selb-20220321.xsd selb-20220321_lab.xml selb-20220321_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "selb-20220321.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "selb-20220321.htm" ] }, "labelLink": { "local": [ "selb-20220321_lab.xml" ] }, "presentationLink": { "local": [ "selb-20220321_pre.xml" ] }, "schema": { "local": [ "selb-20220321.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "selb", "nsuri": "http://www.selectabio.com/20220321", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20220321.htm", "contextRef": "i73063f6d35f844e98fafd1c5ac22c92f_D20220321-20220321", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page Document", "role": "http://www.selectabio.com/role/CoverPageDocument", "shortName": "Cover Page Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20220321.htm", "contextRef": "i73063f6d35f844e98fafd1c5ac22c92f_D20220321-20220321", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.selectabio.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001453687-22-000053-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001453687-22-000053-xbrl.zip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end